|
| Press Releases |
|
 |
|
| Monday, June 23, 2025 |
|
|
Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined with DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeostasis |
| Hua Medicine ("the Company", stock code: 2552.HK) announced today that the Company presented the latest research results of dorzagliatin, its global first-in-class glucokinase activator (GKA), at the 85th Scientific Sessions of the American Diabetes Association (ADA). more info >> |
|
| Friday, March 28, 2025 |
|
|
Hua Medicine Announces 2024 Annual Results |
| Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552) announced the audited full-year results of the Company and its subsidiaries for the year ended December 31, 2024 (the "Reporting Period"), along with the Company's business progress in 2024 and future business outlook. more info >> |
|
| Tuesday, March 18, 2025 |
|
|
Dr. Li Chen Honored as A Leading Figure in Shanghai's Industry and Commerce |
| On March 17th, the highly anticipated 7th Commendation and Exchange Conference for the Leading Figures in Shanghai's Industry and Commerce was brought to a successful conclusion. Dr. Li Chen, the founder and CEO of Hua Medicine, was awarded the title of "A Leading Figure in Shanghai's Industry and Commerce" for his outstanding contributions and innovative leadership in the field of biomedicine. more info >> |
|
| Monday, March 3, 2025 |
|
|
Hua Medicine Awarded Shanghai Innovative Enterprise Headquarters |
| On February 27th, the awarding ceremony of the second batch of Shanghai Innovative Enterprise Headquarters was held in Shanghai. Gong Zheng, Deputy Secretary of Shanghai Municipal Party Committee and Mayor of Shanghai, awarded the certificates to 49 innovative enterprise headquarters, and Hua Medicine was among them. more info >> |
|
| Saturday, November 30, 2024 |
|
|
Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate |
| Hua Medicine (the 'Company', HKEx stock code: 2552) announced today that the Company has successfully completed a Phase I clinical trial on its 2nd generation GKA candidate in U.S. at the 9th China BioMed Innovation and Investment Conference (CBIIC). more info >> |
|
|
Hua Medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC |
| Hua Medicine (the 'Company', HKEx stock code: 2552) announced today that the Company has successfully completed its SENSITIZE study on the mechanism by which dorzagliatin improves the β-cell glucose sensitivity at the 9th China BioMed Innovation and Investment Conference (CBIIC). more info >> |
|
| Friday, October 25, 2024 |
|
|
Founder of Hua Medicine Dr. Chen Li was awarded the 'C.C. Tan Life Science Industrialization Award' |
| The 17th C.C. Tan Life Science Award ceremony was held at Shenyang Pharmaceutical University on October 9th. Dr. Chen Li, Founder and Chief Executive Officer of Hua Medicine, was awarded the C.C. Tan Life Science Industrialization Award . more info >> |
|
| Friday, August 30, 2024 |
|
|
Hua Medicine Announces 2024 Interim Results |
| Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2024 (the "Reporting Period"), and the Company's business progress for the first half of the year and business outlook. more info >> |
|
| Friday, August 25, 2023 |
|
|
Hua Medicine Announces 2023 Interim Results |
| First-in-class glucokinase activator (GKA) HuaTangNing (dorzagliatin) was approved in China in September 2022. more info >> |
|
| Monday, October 10, 2022 |
|
|
Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China |
| Hua Medicine (the "Company", HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company has been approved by the National Medical Products Administration (NMPA) of China on October 8th for two indications more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
15 World Toppers and Near-Perfect Scorers for GIIS Singapore in IBDP 2025 Exams
Jul 7, 2025 20:48 HKT/SGT
|
|
|
Small Businesses Embrace Social -- But Could be Missing a Trick in the Age of AI
Jul 7, 2025 19:00 HKT/SGT
|
|
|
Kincora Secures Strategic North American Investors and Announces Private Placement
Jul 7, 2025 18:39 HKT/SGT
|
|
|
Progress towards potassium-ion batteries 
Jul 7, 2025 14:00 HKT/SGT
|
|
|
Huatai Foundation Supports NbS Summer School, Convening Global Youth to Tackle Ecological Conservation
Jul 7, 2025 10:44 HKT/SGT
|
|
|
MHI Awarded Contract for Basic Design of Japan's Largest CO2 Capture Plant at Hokkaido Electric Power's Tomato-Atsuma Power Station
Jul 7, 2025 11:15 JST
|
|
|
Fujitsu's high-precision skeleton recognition AI adopted to enhance figure skating athlete training
Jul 5, 2025 13:40 JST
|
|
|
Everest Medicines Unveils Breakthroughs in AI+mRNA Platform, Reinforces Global Leadership in Next-Gen mRNA Innovation
Jul 4, 2025 18:59 HKT/SGT
|
|
|
DENSO Acquires Axia Vegetable Seeds to Realize Sustainable Agriculture
Jul 4, 2025 16:20 JST
|
|
|
MHIET Launches 450kW Gas Cogeneration System Capable of Hydrogen Co-Firing
Jul 4, 2025 15:13 JST
|
|
|
INVEST FAIR Malaysia 2025 Spotlights Investor Trends, Multi-Asset Literacy, and Tech-Driven Platforms
Jul 4, 2025 13:00 HKT/SGT
|
|
|
Yachiyo Engineering and NEC launch adaptation finance study in Indonesia to calculate the adaptation value of disaster prevention measures
Jul 4, 2025 13:25 JST
|
|
|
Fujitsu to implement store monitoring solution for METRO Inc. in Canada, enhancing operational efficiency and policy compliance
Jul 4, 2025 13:19 JST
|
|
|
Chinabank Fully Transitions Into AI-powered Human Capital Management
Jul 3, 2025 20:30 HKT/SGT
|
|
|
UOB Hong Kong becomes first Singapore-based bank to sign MOU with HKTDC
Jul 3, 2025 16:29 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
